What does LO-PHARMA do?

LO-PHARMA is a pharmacy in Lubbeek. Private Limited, started on 23 October 2008, 1 establishment.

What is the address of LO-PHARMA?

The registered office of LO-PHARMA is located at Lostraat(PEL) 54, 3212 Lubbeek.

Is LO-PHARMA still active?

Yes. According to the CBE (31 October 2026) LO-PHARMA is active, legal situation “Normale toestand”, started on 23 October 2008.

Is LO-PHARMA registered on Peppol?

Yes, LO-PHARMA is registered on the Peppol network with ID 0208:0807456110.

What is the enterprise number of LO-PHARMA?

The enterprise number of LO-PHARMA is BE0807456110.

When was LO-PHARMA founded?

LO-PHARMA was founded on 23 October 2008.

Who are the directors of LO-PHARMA?

According to the 2025 annual accounts, the directors of LO-PHARMA are: L&F Health.

Is LO-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 October 2008; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did LO-PHARMA make in 2025?

LO-PHARMA recorded a loss after taxes of € 15,388 in financial year 2025.

What is the revenue of LO-PHARMA?

As a small company, LO-PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 150,129.

How much does an employee at LO-PHARMA earn?

The average wage cost per full-time employee at LO-PHARMA was € 69,200 in 2025: staff costs of € 89,967 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does LO-PHARMA have?

According to the 2025 annual accounts, LO-PHARMA has 1.3 full-time equivalents (FTE).

LO-PHARMA (Private Limited) - Lubbeek - BE0807456110

Dossier LO-PHARMA, printed on 1 November 2026 from databakkes.be/en/0807456110/lo-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.
Shrinking team NBB

FTE fell two years in a row, from 1.7 to 1.3.

Financials

Financial year 2025

LO-PHARMA from Lubbeek, company number BE0807456110, closed financial year 2025 with a result of € -15,388 after tax. For that financial year LO-PHARMA recorded a gross margin of € 150,129 and equity of € 79,136. Compared with financial year 2024, the result moved from € 21,894 to € -15,388. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Healthy

€ 79,136

▼ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -15,388

▼ still € 21,894 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53,775

▼ 22% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 59,136.

People and assets in 2025

Full-time equivalents

1.3

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 89,967

▲ 7% vs 2024

€ 69,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 20,457

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 366,598

▼ 15% vs 2024

€ 68,305 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 47,695

▼ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 11,971

▼ 32% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 190,641 Gross margin 2022: € 190,641 First fiscal year in the series	€ 189,795 Gross margin 2023: € 189,795 Unchanged (€ 190,641) Unfavourable step	€ 188,417 Gross margin 2024: € 188,417 ▼ 1% vs 2023 (€ 189,795) Unfavourable step	€ 150,129 Gross margin 2025: € 150,129 ▼ 20% vs 2024 (€ 188,417) Unfavourable step	▼ 20%
Profit after taxes	€ 14,715 Profit after taxes 2022: € 14,715 First fiscal year in the series	€ 14,359 Profit after taxes 2023: € 14,359 ▼ 2% vs 2022 (€ 14,715) Unfavourable step	€ 21,894 Profit after taxes 2024: € 21,894 ▲ 52% vs 2023 (€ 14,359) Favourable step	€ -15,388 Profit after taxes 2025: € -15,388 ▼ € 37,281 vs 2024 (€ 21,894) Unfavourable step	▼ € 37,281
Equity	€ 72,271 Equity 2022: € 72,271 First fiscal year in the series	€ 72,629 Equity 2023: € 72,629 Unchanged (€ 72,271) Favourable step	€ 94,523 Equity 2024: € 94,523 ▲ 30% vs 2023 (€ 72,629) Favourable step	€ 79,136 Equity 2025: € 79,136 ▼ 16% vs 2024 (€ 94,523) Unfavourable step	▼ 16%
Total debts	€ 619,228 Total debts 2022: € 619,228 First fiscal year in the series	€ 629,796 Total debts 2023: € 629,796 ▲ 2% vs 2022 (€ 619,228) Unfavourable step	€ 604,474 Total debts 2024: € 604,474 ▼ 4% vs 2023 (€ 629,796) Favourable step	€ 518,431 Total debts 2025: € 518,431 ▼ 14% vs 2024 (€ 604,474) Favourable step	▼ 14%
Cash	€ 69,475 Cash 2022: € 69,475 First fiscal year in the series	€ 53,675 Cash 2023: € 53,675 ▼ 23% vs 2022 (€ 69,475) Unfavourable step	€ 69,093 Cash 2024: € 69,093 ▲ 29% vs 2023 (€ 53,675) Favourable step	€ 53,775 Cash 2025: € 53,775 ▼ 22% vs 2024 (€ 69,093) Unfavourable step	▼ 22%
Land & buildings	€ 344,247 Land & buildings 2022: € 344,247 First fiscal year in the series	€ 321,527 Land & buildings 2023: € 321,527 ▼ 7% vs 2022 (€ 344,247) Unchanged	€ 299,229 Land & buildings 2024: € 299,229 ▼ 7% vs 2023 (€ 321,527) Unchanged	€ 279,902 Land & buildings 2025: € 279,902 ▼ 6% vs 2024 (€ 299,229) Unchanged	▼ 6%
Retained profit	€ 52,271 Retained profit 2022: € 52,271 First fiscal year in the series	€ 52,629 Retained profit 2023: € 52,629 ▲ 1% vs 2022 (€ 52,271) Favourable step	€ 74,523 Retained profit 2024: € 74,523 ▲ 42% vs 2023 (€ 52,629) Favourable step	€ 59,136 Retained profit 2025: € 59,136 ▼ 21% vs 2024 (€ 74,523) Unfavourable step	▼ 21%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 14,000 Dividend 2023: € 14,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 14,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 516,045 Bank debt 2022: € 516,045 First fiscal year in the series	€ 442,762 Bank debt 2023: € 442,762 ▼ 14% vs 2022 (€ 516,045) Favourable step	€ 431,627 Bank debt 2024: € 431,627 ▼ 3% vs 2023 (€ 442,762) Favourable step	€ 366,598 Bank debt 2025: € 366,598 ▼ 15% vs 2024 (€ 431,627) Favourable step	▼ 15%
Balance sheet total	€ 691,499 Balance sheet total 2022: € 691,499 First fiscal year in the series	€ 702,426 Balance sheet total 2023: € 702,426 ▲ 2% vs 2022 (€ 691,499) Unchanged	€ 698,997 Balance sheet total 2024: € 698,997 Unchanged (€ 702,426) Unchanged	€ 597,566 Balance sheet total 2025: € 597,566 ▼ 15% vs 2024 (€ 698,997) Unchanged	▼ 15%
Employees (FTE)	1.5 Employees (FTE) 2022: 1.5 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 ▲ 0.2 vs 2022 (1.5) Unchanged	1.5 Employees (FTE) 2024: 1.5 ▼ 0.2 vs 2023 (1.7) Unchanged	1.3 Employees (FTE) 2025: 1.3 ▼ 0.2 vs 2024 (1.5) Unchanged	▼ 0.2

Key figures of LO-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LO-PHARMA?

What happened at LO-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: loss of € 15,388 (▼ € 37,281 vs 2024). Source: NBB ↗
Oct 23, 2008 New establishment in Lubbeek. KBO
2008 L&F Health became a director. NBB
Oct 23, 2008 Start of the company according to the CBE. KBO

In short

From € 14,715 profit in 2022 to € 15,388 loss in 2025.

Paid € 16,902 in corporate taxes since 2022.

Best year ever: 2024, with € 21,894 profit.

On average € 115,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

L&F HEALTH 100%

The stake of L&F HEALTH comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

LO-PHARMA

Behind LO-PHARMA is L&F Health. The shares are held by L&F HEALTH (100%).

Directors

According to the 2025 annual accounts

L&F Health

Director · represented by Marthe Frans Lambrechts

since 2008

Shareholders

L&F HEALTH

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Lostraat(PEL) 54

3212 Lubbeek

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

L&F HEALTH same network

€ 42,707 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0807.456.110
VAT number: BE 0807.456.110
Registered office: Lostraat(PEL) 54, 3212 Lubbeek
Names & denominations: LO-PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 23 October 2008
Peppol: Active · Active since 1 Jan 2001
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗